title: Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
abstract: BACKGROUND
  The ability to predict symptom response to reflux oesophagitis-healing therapy may optimize treatment decisions.
  
  
  OBJECTIVE
  To identify factors associated with heartburn resolution in patients receiving acid-suppressive therapy for reflux oesophagitis.
  
  
  METHODS
  In this multicentre, randomized, double-blind trial (EXPO; AstraZeneca study code: SH-NEG-0008), patients with endoscopically confirmed reflux oesophagitis and reflux symptoms received once-daily proton pump inhibitor therapy [esomeprazole 40 mg (n = 1562) or pantoprazole 40 mg (n = 1589)] for >or=4 weeks. Factors associated with heartburn resolution after 4 weeks were identified by multiple logistic regression analysis.
  
  
  RESULTS
  Esomeprazole therapy, positive Helicobacter pylori status and greater age were associated with an increased likelihood of heartburn resolution [odds ratio (95% confidence interval): 1.31 (1.12, 1.54), 1.44 (1.19, 1.74) and 1.013 (1.007, 1.019) per year, respectively; all P < 0.001]. Men and patients with no acid regurgitation or epigastric pain pre-treatment were also more likely to achieve heartburn resolution (all P < 0.05).
  
  
  CONCLUSIONS
  The use of esomeprazole rather than pantoprazole increases the probability of achieving resolution of heartburn during reflux oesophagitis-healing therapy. Other factors, including H. pylori status, age, gender and symptom profile may be helpful in determining the likelihood of heartburn resolution in such patients.
authors.affiliation: Medical Department, Ev. Jung-Stilling Hospital, Siegen, Germany. J.Labenz@t-online.de
authors.forename: J
authors.initials: J
authors.lastname: Labenz
authors.forename: D
authors.initials: D
authors.lastname: Armstrong
authors.forename: S
authors.initials: S
authors.lastname: Zetterstrand
authors.forename: S
authors.initials: S
authors.lastname: Eklund
authors.forename: A
authors.initials: A
authors.lastname: Leodolter
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D064098:Esomeprazole / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D006356:Heartburn / Q000188:drug therapy; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D000077402:Pantoprazole; D064098:Esomeprazole